Achieving high remission rate with use of autologous HSCT, thalidomide maintenance and non-myeloablative allogeneic HSCT in patients with multiple myeloma.

Oyan B., Koc Y., Kars A., Turker A., Tekuzman G., Kansu E.

45th Annual Meeting of the American-Society-of-Hematology, SAN DIEGO, CALIFORNIA, 6 - 09 December 2003, vol.102, (Summary Text) identifier

  • Publication Type: Conference Paper / Summary Text
  • Volume: 102
  • City: SAN DIEGO
  • Country: CALIFORNIA
  • Acibadem Mehmet Ali Aydinlar University Affiliated: No